Drug Trial Radar · NCT00478205
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Jul 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,467
Actual
Start
Jun 2007
Primary completion
Jun 2009
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- Eisai Limited
- First posted
- May 24, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 45 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.
Conditions
- Alzheimer's Disease
Interventions
Aricept (donepezil SR 23 mg)Drug
Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design: 23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation.
Aricept (donepezil IR 10 mg)Drug
Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design: 10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 24 in SIB Total ScoreTime frame: Baseline and Week 24
- Overall Change From Baseline in Modified CIBIC+ to Week 24Time frame: Baseline and Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MedTrials, Inc.
Hickory, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.